The schematic should include: 1. CRISPR-Cas9 Components â Cas9 protein bound to a single guide RNA; PAM (NGG) adjacent to the target sequence. 2. BCL11A Gene Structure â show the erythroid enhancer region within BCL11A. 3. DNA Cleavage Site â indicate the double-strand break within the enhancer sequence. 4. Downstream Effect â reduced BCL11A â derepressed Îł-globin â increased fetal hemoglobin (HbF). Safety Consideration â off-target editing is a key FDA concern; genome-editing therapies must demonstrate minimal unintended edits and thorough long-term monitoring
Instant Quality - Flux Pro 1.1